Allergy & Immunology billing is one of the most technically demanding specialties in all of medicine. You bill for allergy testing by method, number, and allergen category. You bill for immunotherapy by formulation type, administration route, and dose stage. You manage prior authorization for six different biologic drugs — each with distinct step therapy requirements, diagnosis criteria, and payer-specific protocols. Without a billing team that knows A&I inside out, you lose money on every test panel, every injection visit, and every biologic administration. ParaMed's A&I-certified billing specialists know every rule in every category — and keep your revenue cycle as precise as your clinical protocols.
Each category has its own CPT code family, its own documentation requirements, and its own compliance rules. ParaMed manages all four — at specialty-certified precision.
Allergy testing billing is unit-based — you bill per test, per method, and within strict unit limits that vary by test type. Percutaneous skin prick tests (95004), intradermal tests (95024/95028), patch tests (95044), and in-vitro serum testing (86003/86001) each have different per-unit reimbursement, different maximum billable units per session, and different documentation requirements. The critical skill is knowing the NCCI edit rules, the documentation standard for each test type, and the payer-specific maximum units — and applying all three correctly on every testing encounter.
Immunotherapy billing requires understanding the separation between allergen preparation (the professional service of formulating the extract) and allergen administration (the injection service). Both are billable, often by different providers. SCIT bills for extract preparation by stinging insect (95145–95149) or inhalant allergen (95165) and administration codes (95115, 95117) per injection visit. The build-up vs. maintenance phase distinction matters for both documentation and medical necessity. Each component must be correctly separated, attributed to the right provider, and billed with the correct units and modifiers.
Biologics administered in the allergy office represent some of the highest-value claims in the specialty — and the most PA-intensive. Omalizumab (Xolair, J2357), dupilumab (Dupixent, J0223), mepolizumab (Nucala, J2182), benralizumab (Fasenra, J0517), tezepelumab (Tezspire, J3241) each require specific J-code billing with NDC documentation, dose-accurate quantity units, administration code billing (96372), and a prior authorization process that varies by drug, by indication, and by payer. Missing any component costs hundreds to thousands of dollars per visit.
Asthma management includes pulmonary function testing billing (spirometry 94010, pre/post-bronchodilator 94060, methacholine challenge 94070) and E/M coding at appropriate complexity levels. Immune deficiency billing covers IVIG administration (90284 + J-codes for IVIG products), SCIG subcutaneous immunoglobulin (J1559/J1561), and the complex prior authorization management for immunoglobulin products. Each immunoglobulin product has a specific J-code, dose-based unit calculation, and PA criteria. In-office administration vs. home infusion billing have completely different rules.
These are the billing failures we find in virtually every allergy & immunology practice operating with generalist billing. Each one is measurable, preventable, and compounding every week.
Allergy skin testing is billed per unit. When billing teams enter a flat CPT code without accurately counting the number of allergens tested, you receive reimbursement for one unit when you've performed 40, 60, or 80 units. The difference between billing 95004 x 1 and 95004 x 60 is the entire revenue value of the test. Unit accuracy on testing encounters is the single most impactful billing correction for most allergy practices.
$40–$120Lost per testing encounter from unit errorsSCIT billing has two separately billable components: the allergen preparation service (95165 for inhalant, 95145–95149 for venom) and the allergen injection administration (95115, 95117). Many generalist billing teams know to bill for the injection administration but don't understand that the extract preparation is a separately billable professional service. Missing the preparation component is a persistent revenue gap that compounds with every immunotherapy patient on your panel.
50% revenueLost when preparation component omitted from SCIT billingEach biologic drug has a specific J-code, and the unit count reflects a specific dose increment. Omalizumab (J2357) is billed per 5mg — a 300mg dose requires 60 units. Dupilumab (J0223) is billed per 1mg — a 300mg dose requires 300 units. When billing teams enter the wrong J-code or unit count, the claim either denies, reimburses at the wrong level, or triggers a compliance audit. For drugs that reimburse at $800–$3,000+ per dose, a unit calculation error can cost hundreds to thousands of dollars.
$200–$2,400+Per biologic dose from J-code or unit calculation errorEvery biologic used in allergy requires prior authorization from virtually every commercial payer and Medicare Advantage plan. Each PA has an expiration date; most require annual renewal. When a biologic is administered without an active, valid PA, the entire claim denies. For a drug that costs $800–$3,000+ per administration with 4-8 administrations per year, a single PA lapse can represent $3,200–$24,000 in revenue placed at risk.
$3,200–$24K/yrAt risk per biologic patient without active PA trackingPatch testing (95044) is billed per antigen — a standard panel with 36 antigens is coded as 95044 x 36. Reading patch tests requires two separate professional readings at different time intervals — and each reading encounter is separately billable as an office visit. Many practices bill a flat single unit instead of per-antigen units, or fail to bill both readings, systematically losing significant revenue on a service that supports full billing.
70–80% reductionIn patch test revenue from flat-unit billing instead of per-antigen countWhen an allergy evaluation (E/M service) and testing are performed on the same day by the same provider, the E/M is separately billable — but only with Modifier -25 indicating it was a significant, separately identifiable service beyond the pre-test assessment. Without Modifier -25 with supporting documentation, the E/M is bundled into the testing encounter under NCCI and denied.
E/M denialOn every same-day test visit without documented Modifier -25 justificationPulmonary function testing has multiple separately billable components: the spirometry (94010 or 94060 for pre/post bronchodilator, which includes both measurements), the flow-volume loop (94375), and bronchodilator administration (J7613 for albuterol). When only the base spirometry code is billed without the pre/post bronchodilator component or without the bronchodilator administration, revenue is systematically missed on a frequently performed service.
$45–$90Per PFT encounter from incomplete pre/post bronchodilator component billingAllergen immunotherapy billing follows the clinical protocol — and the billing rules change at each phase of treatment. Understanding which codes apply in build-up vs. cluster vs. maintenance, and how to correctly separate preparation from administration, is essential to capturing full immunotherapy revenue.
Billing rules, CPT codes, and documentation requirements by treatment phase
Weekly injections increasing from low to high dose over 3–7 months. Each visit: administration code (95115 or 95117) + preparation component separately billed by allergist.
Multiple injections per visit on multiple days — rapid build-up. Each injection on each day is separately billable with 95117 (2+ injections). Pre-medication administered in-office is separately billable when physician-administered.
Monthly injections at maintenance dose indefinitely. Preparation code billing (95165) continues. Documentation of maintenance dose and clinical response required at each visit.
Stinging insect venom immunotherapy uses entirely separate codes from inhalant SCIT. Preparation codes 95145–95149 vary by number of insect species in the formulation. Same administration codes apply.
Injection-based — highest reimbursement, most complex billing
95165 (inhalant, per dose) or 95145–95149 (venom, per species) — the allergist's professional work in formulating and maintaining the antigen extract. Separately billable from the injection administration.
95165 / 95145–9514995115 for a single injection visit, 95117 when 2 or more injections are administered in the same visit. Both codes bill the complete injection service including the 30-minute observation period.
95115 / 95117Post-injection observation is clinically required (30 minutes standard) and included in the administration code — do not separately bill for observation. If an anaphylactic reaction occurs requiring treatment, emergency management is separately billable.
99211 for injection supervision if NP/PA administersWhen the allergist prepares the extract but a nurse or MA administers the injection, the preparation is billed under the allergist, and the administration may require specific billing handling based on the supervision level and setting.
Modifier rules apply for split-billingDrop/tablet-based — different billing pathway, growing utilization
FDA-approved sublingual immunotherapy tablets (Grastek, Ragwitek, Odactra) have specific HCPCS codes. Coverage by commercial payers is inconsistent — many require PA and some don't cover SLIT at all.
J3490 / specific HCPCS per productCompounded sublingual immunotherapy drops are not FDA-approved and are not covered by Medicare or most commercial payers. Practices offering compounded SLIT must have a clear patient financial responsibility policy.
Patient-pay — no insurance billingThe E/M visit at which SLIT is prescribed and therapy is initiated is fully billable as a standard office visit. Follow-up visits for SLIT therapy monitoring are also separately billable E/M services.
99213–99215 + SLIT product codeFor payers that do cover FDA-approved SLIT tablets, coverage requires documentation of the specific allergen sensitivity, prior treatment history, and the clinical rationale for SLIT over SCIT.
PA required by most payers for SLIT tabletsSelect any billing category to explore specific CPT codes, reimbursement benchmarks, and the billing rules that determine whether your claims are paid at maximum defensible value or quietly denied.
Skin prick, intradermal, in vitro
SCIT, SLIT, venom
Omalizumab, dupilumab, more
Spirometry, challenge, IVIG
Every allergy test type has a different CPT code and a different unit-counting rule. The unit count on every testing claim must match the exact number of tests performed in each category — and must comply with NCCI same-day combination restrictions.
Prick or scratch method, per allergen tested. A 60-allergen panel = 95004 x 60. Must list allergens tested with results for each.
Intradermal allergy skin testing, without re-test. Higher reimbursement per unit than percutaneous but strict unit limits apply per session per payer.
Contact allergy patch testing, billed per antigen applied. Standard T.R.U.E. TEST = 36 antigens = 95044 x 36. Requires two timed readings.
Serum IgE testing for specific allergen sensitivity — lab-based. Each allergen tested = one unit. Must be correctly attributed when ordered and interpreted by the allergist in the office.
Oral food or drug challenge test, first 120 minutes of monitoring. 95079 is each additional 60 minutes. Requires documentation of challenge protocol, observed reactions, and clinical outcome.
Intradermal testing with re-test for delayed hypersensitivity reaction — two readings required. Both 15-minute and 4–8 hour readings must be documented.
The unit count on 95004 or 95024 must equal the exact number of individual allergens tested. A 60-allergen panel is 95004 x 60, not 95004 x 1. Unit errors are the single most common and most costly allergy testing billing mistake.
Percutaneous (95004) and intradermal (95024/95028) tests may be billed on the same day when medically necessary — but specific NCCI rules apply. Documentation must support the medical necessity of performing both test methods.
When an allergy evaluation and testing are on the same day, the E/M requires Modifier -25 and documentation that the evaluation addressed a clinical decision beyond the testing order. Without -25, the E/M is bundled and denied.
The most important rule in immunotherapy billing: there are two separately billable services — allergen preparation and allergen administration. Both must be identified, correctly coded, and submitted. Missing either component writes off half or more of your immunotherapy revenue.
Administration of a single allergen injection per visit. Includes the 30-minute post-injection observation period. Billed per visit, not per injection when only one extract is administered.
Administration of two or more allergen injections per visit. A patient receiving separate left-arm and right-arm injections = 95117, not two 95115 codes.
The allergist's professional service of preparing and maintaining the allergen extract — per dose. The most frequently missed immunotherapy billing component. Separately billable from the injection administration.
Extract preparation for a single stinging insect venom species. 95145 (1 species) through 95149 (5 species). Significantly higher reimbursement per dose than inhalant SCIT preparation.
Rapid desensitization protocol for drug allergy — per hour. First hour: 95180; each additional hour: 95199. High-intensity monitoring service with distinct documentation requirements.
Venom immunotherapy — professional service component only (no supply). Used when the physician provides professional management services for venom immunotherapy being administered at another facility.
95165/95145-95149 (preparation) and 95115/95117 (administration) are both separately billable. Never omit the preparation component — it represents a significant share of total immunotherapy revenue.
When two injections are given in one visit, bill 95117 once — not 95115 twice. NCCI edit rules prohibit two 95115 codes on the same date of service for the same patient.
During build-up, the increasing dose at each visit should be documented — both for clinical reasons and to support the continued medical necessity of the increasing-dose protocol.
Each biologic used in allergy has a specific J-code billed per dose-accurate unit, requires NDC documentation, must have active prior authorization, and must be accompanied by a separately billed administration code. All five requirements must be met on every biologic claim.
Anti-IgE monoclonal antibody for moderate-severe allergic asthma and chronic idiopathic urticaria. 300mg dose = 60 units. Weight/IgE-based dosing table documentation required.
IL-4/IL-13 antagonist for atopic dermatitis, asthma, CRSwNP, and eosinophilic esophagitis. 300mg dose = 300 units. High PA burden with indication-specific criteria.
Anti-IL-5 for severe eosinophilic asthma. 100mg subcutaneous every 4 weeks. Bill as J2182 x 100 units. Different PA processes for asthma vs. EGPA indication.
Anti-IL-5Rα for severe eosinophilic asthma. 30mg subcutaneous — every 4 weeks for first 3 doses, then every 8 weeks. Bill as J0517 x 30.
Anti-TSLP for severe uncontrolled asthma regardless of eosinophil count. 210mg subcutaneous every 4 weeks. NDC documentation critical as code is relatively new.
Billed separately from the J-code for every biologic administered in a non-facility setting. The J-code covers the drug; 96372 covers the professional administration service. Both must appear on every biologic claim.
J2357 (omalizumab) = per 5mg, so 300mg ÷ 5mg = 60 units. J0223 (dupilumab) = per 1mg, so 300mg = 300 units. Every biologic has a different unit calculation — errors mean under-payment or audit exposure.
The National Drug Code (NDC) from the specific lot/package administered must be documented with every J-code claim. Missing NDC documentation is a direct cause of biologic drug claim denials.
Every biologic requires active, valid PA before administration. Track PA expiration dates and submit renewal requests 4–6 weeks before expiration. Administering without active PA results in full claim denial.
PFT performed in the allergy office generates multiple separately billable components depending on the tests performed and whether pre/post bronchodilator measurements are included. Identifying and billing every component on every PFT encounter is the key to capturing full asthma service revenue.
Spirometry with graphic record, without bronchodilator. NOT billable when pre/post bronchodilator is performed — 94060 replaces 94010 when pre/post is done.
Spirometry performed before AND after bronchodilator administration. Includes both measurements in one code — do NOT bill 94010 in addition to 94060. Bronchodilator administration (J7613) separately billable.
Methacholine or other bronchospasm provocation testing with multiple spirometric determinations. Requires documentation of baseline spirometry, methacholine doses administered, and clinical interpretation.
IV infusion of immunoglobulin — first hour. 96366 for each additional hour. The immunoglobulin J-code (J1566/J1557/J1561 by product) is billed separately.
Immunoglobulin G product code — billed per 500mg. Brand-specific J-codes are required (J1566 for Gamunex-C, J1557 for Gammaplex, J1559 for Hizentra SCIG). Using J3490 when a specific code exists creates audit risk.
Albuterol inhalation solution administered in-office during spirometry or for acute bronchospasm — separately billable from the spirometry code. Billed per milligram of albuterol used.
When pre-bronchodilator AND post-bronchodilator spirometry is performed in the same session, bill 94060 only — not 94010 plus 94060. NCCI bundles these codes — billing both creates a duplicate billing flag.
The bronchodilator administered during pre/post spirometry is NOT included in the 94060 code — it is separately billable as J7613 when administered from office stock.
Each IVIG product has its own J-code — using J3490 (not otherwise classified) when a specific J-code exists for the product billed creates audit exposure. Document the specific product NDC on every IVIG claim.
Biologics in allergy & immunology carry the most complex prior authorization requirements in the specialty — step therapy mandates, eosinophil count criteria, diagnosis-specific PA processes, and annual renewal requirements. One PA failure on a single biologic claim can cost thousands of dollars in denied revenue.
Every allergy testing service with CPT code, unit structure, typical Medicare reimbursement benchmark, and critical billing notes — all in one reference table.
Select any service below to see exactly what our A&I-certified billing team delivers — with the specialty detail that transforms each service from a cost center into a revenue driver for your allergy and immunology practice.
Our A&I coders are trained on the per-unit billing rules for every testing method — percutaneous (95004), intradermal (95024/95028), patch testing (95044 per antigen), provocation challenge (95076/95079), and in vitro serum IgE testing (86003). For every testing encounter, we verify the unit count from the testing record, apply the correct code family based on testing method, confirm NCCI edit compliance for same-day test combinations, and apply Modifier -25 with documentation review when E/M services were performed on the same day.
Every testing claim unit count is verified against the allergen testing record before submission — not estimated or defaulted to a standard panel number.
Testing claims are reviewed for documentation of allergen list tested with results, testing method, and reading time — the elements payers require for testing claims.
Same-day testing combinations are checked against current NCCI edit tables before submission — preventing automatic denials from prohibited code combinations.
Maximum billable units per session vary by payer — we maintain payer-specific unit limit rules and apply them pre-submission to prevent maximum-unit denials.
Our immunotherapy billing process captures both billable components on every immunotherapy encounter: the extract preparation professional service (95165 for inhalant, 95145–95149 for venom by species count) and the injection administration (95115 for single-extract visits, 95117 for multi-extract visits). We track each patient's immunotherapy protocol — build-up, cluster, or maintenance — and apply the correct billing approach based on the phase. Venom immunotherapy uses a separate code family from inhalant SCIT and requires tracking by species count for preparation billing.
No immunotherapy encounter is submitted without verifying that both the preparation and administration components have been captured.
For venom immunotherapy patients, the species count in the preparation determines the preparation code (95145–95149). We verify species count from the clinical venom protocol.
The patient's current treatment phase is tracked — build-up patients generate higher monthly administration revenue (weekly visits) vs. maintenance patients (monthly visits).
When the allergist prepares the extract and nursing staff administers the injection, billing attribution is correctly assigned per provider with appropriate modifier and supervision level documentation.
Our biologic billing process covers every step from PA submission to claim payment. Prior to initial biologic administration, we manage the PA submission process — compiling step therapy documentation, eosinophil count records, prior medication failure documentation, and diagnosis-specific criteria into a complete PA package. After PA approval, we track the authorization validity window and generate PA renewal requests 4–6 weeks before expiration. For every biologic administration, we verify the J-code, calculate the dose-to-unit conversion, document the NDC, and submit both the J-code and 96372 administration code on the claim.
Each biologic has a different unit increment in its J-code. We maintain a drug-specific unit calculation reference and verify the unit count on every biologic claim against the administered dose.
Every active biologic PA has its expiration date tracked. Renewal requests are triggered automatically at the 4–6 week pre-expiration window so biologics are never administered without active coverage.
All biologic claims are flagged for priority follow-up at 15 days post-submission — confirming adjudication status and identifying any pend or denial requiring immediate response.
Each biologic PA submission is built specifically for the drug and indication — not a generic template. Omalizumab for asthma vs. omalizumab for urticaria use entirely different PA documentation packages.
Allergy & immunology denials require clinical billing knowledge to appeal effectively. A testing unit-count denial requires an appeal that references the allergen testing record and explains the per-unit billing methodology. A biologic PA denial requires a peer-to-peer process with clinical documentation of the step therapy completed and the clinical criteria met. Our denial management team builds every A&I appeal on the specific clinical and billing logic relevant to the denied service — not generic form letters.
Biologic drug denials receive a 72-hour response initiation standard. Testing and immunotherapy denials are worked within 5 business days.
Every A&I appeal is built on the specific billing rule or clinical documentation standard relevant to the denied service.
Denial patterns are analyzed monthly — recurring denials in the same code category trigger a pre-submission process change to prevent the denial from occurring again.
When biologic PA is denied on initial submission, we coordinate the peer-to-peer review process — preparing the clinical documentation package for the allergist's peer-to-peer call.
Our monthly A&I performance reports break down revenue, denial rates, and collection rates across all four service categories — testing, immunotherapy, biologics, and E/M. Reports include testing revenue per encounter (with unit-count accuracy metrics), immunotherapy revenue per patient (preparation + administration combined), biologic revenue per patient by drug with PA success rate, and compliance metrics for high-risk billing areas (Modifier -25 usage, NCCI edit compliance, NDC documentation rate). Every monthly report includes a comparison to the prior month's baseline and the pre-engagement audit finding.
Revenue is broken down by service line in every monthly report — testing vs. immunotherapy vs. biologics vs. E/M — so you can see exactly which category is performing.
Key compliance metrics tracked monthly: Modifier -25 usage rate, NDC documentation compliance, testing unit-count accuracy rate, and biologic PA validity rate.
Every metric is compared to the pre-engagement audit baseline. Your monthly report shows exactly what has improved since ParaMed started managing your billing.
When any metric shows a statistically significant decline vs. the prior month, our analytics system flags it for immediate root-cause investigation.
Allergy & immunology payer rules vary more than almost any other specialty — testing unit limits, biologic PA criteria, immunotherapy coverage policies, and SLIT coverage determinations all differ payer by payer.
Medicare covers most allergy testing, immunotherapy, and medical management services — with LCD-based coverage for specific testing procedures and biologic drugs based on NCD/LCD criteria.
MA plans follow Medicare coding rules but frequently have more restrictive biologic PA requirements and may have testing unit limits more restrictive than traditional Medicare.
Commercial payers cover allergy services but have widely varying testing unit limits, biologic PA criteria, and immunotherapy coverage policies. Commercial plans are the most variable payer segment for A&I billing.
UHC has extensive A&I medical policies covering testing limits, biologic step therapy requirements, and immunotherapy coverage — among the most complex of the national commercial payers for allergy services.
State Medicaid programs vary widely in allergy coverage — most cover basic allergy evaluation but have limited or inconsistent coverage for testing, immunotherapy, and biologics.
Some commercial plans redirect biologic administration to specialty pharmacy — requiring different billing workflows and drug acquisition processes.
Generalist billing average
A&I specialty standard
Every A&I onboarding starts with a free specialty audit covering testing unit accuracy, immunotherapy billing gaps, biologic PA status, and spirometry code completeness — delivered as a written report within 48 hours.
We review a 90-day sample of your claims — testing unit counts, immunotherapy preparation billing, biologic J-code accuracy and PA status, and spirometry code selection. Written revenue impact report in 48 hours.
We document your complete A&I service mix — testing methods, immunotherapy protocols (SCIT/SLIT/venom), biologic drugs administered with dosing schedules, spirometry services — and build your practice-specific billing protocol with payer-specific unit limits.
We establish a PA tracking calendar for every biologic patient — documenting current PA status, expiration dates, and renewal windows. Any PA approaching expiration receives an immediate renewal submission.
First A&I claims submitted within 24 hours of documentation receipt. Every testing claim is reviewed for unit count accuracy. Every biologic claim is verified for J-code, unit calculation, NDC, and active PA before submission.
First monthly dashboard delivered — service-line revenue breakdown (testing, immunotherapy, biologics, E/M), denial rate by category, biologic PA success rate, and a direct comparison vs. the pre-engagement audit baseline.
Real outcomes from allergists, immunologists, and A&I practice administrators who replaced generalist billing with ParaMed's specialty-certified team.
"Our previous billing team had been billing 95004 x 1 on every testing encounter for years. A standard 60-allergen prick test panel was being submitted as one unit when it should have been 60 units. ParaMed audited six months of testing claims and quantified the under-billing at $2,800 per month — $33,600 per year — from that single unit-counting error alone. After correcting it, our testing revenue per encounter increased by an average of $74. That's real money that was just being left on the table."
"We administer omalizumab, dupilumab, and mepolizumab in-office — all three required prior authorization from our patient population's diverse payer mix. We had experienced four PA lapses in one year, resulting in three biologic claims totaling over $11,000 that were fully denied. ParaMed took over biologic billing, established a PA tracking calendar for all 23 of our biologic patients. In 18 months under ParaMed, we have had zero PA lapses. Zero. The claims that were previously denied are now being paid. The math speaks for itself."
"The immunotherapy preparation billing issue was invisible to us because we didn't know it existed. Our billing team was billing 95115 for every injection visit — the administration code — but never billing 95165 for the extract preparation professional service. ParaMed identified this in the audit and explained that the preparation component is worth $7–10 per dose. Across our 180 active immunotherapy patients receiving monthly maintenance injections, that was $1,260–$1,800 per month in unbilled revenue. It's now being captured on every immunotherapy encounter."
We review your testing unit accuracy, immunotherapy preparation billing, biologic J-code correctness, PA status for every active biologic patient, and spirometry code completeness — and deliver a written revenue impact report within 48 hours showing exactly what your practice is leaving behind in each category.
We sample your recent allergy testing claims and compare the billed unit count against the allergen testing records — quantifying the per-encounter and monthly revenue gap from unit undercounting across all testing methods.
We check whether your immunotherapy billing includes the extract preparation component (95165/95145–95149) on every encounter — and calculate the monthly revenue impact of the preparation code gap across your active immunotherapy patient panel.
We review your biologic claims for J-code accuracy, unit calculation correctness, and NDC documentation completeness — and check the current PA status for every active biologic patient, identifying any PAs approaching expiration or already lapsed.
All findings are documented with specific dollar estimates per revenue category — so you have a precise, per-category ROI calculation before making any decision about changing your billing approach.
"The audit found $33,600 per year in testing revenue from unit-counting alone, plus $15,000 in missed preparation codes, plus $11,000 in biologic claims that had been denied for PA lapses. I signed the agreement before I'd finished reading the report."
No cost. No commitment. A written report showing exactly what your allergy & immunology practice is leaving behind — across all four A&I revenue categories.
Audit covers: Testing unit accuracy, immunotherapy preparation, biologic J-codes, PA status, spirometry codes, Modifier -25 compliance
From the unit count on a 60-allergen prick test panel to the exact J-code unit calculation on a dupilumab administration to the PA renewal that prevents a $3,000 biologic denial — ParaMed's A&I-certified billing specialists manage every detail of your allergy and immunology revenue cycle with the precision that your clinical work demands and your practice finances require.
Trusted by Practices Across US — Feedback from providers who rely on ParaMed for smarter Medical Billing.
